$2.25-13.5%Nov 12 close
Reported results on November 13, 2026; they are not in these figures yet.
Figures through September 30, 2026, from the 10-Q filed November 12, 2026
Just reported
From Beyond AIR, Inc.'s results release of November 13, 2026; its quarterly report has since been filed.
Actual
$2.3M
+28% y/y
+31% q/q
Guided
—
No guide given
Actual
-$3.76
Guided
—
No guide given
Actual
-$6M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2.3M | $1.8M | +27.83% |
| Profit | -$7.8M | -$7.9M | +1.54% |
| Profit per share | -$3.76 | -$2.96 | -27.03% |
| Free Cash Flow | -$6.3M | -$4.7M | -34.48% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Beyond AIR, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Beyond AIR, Inc.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.